Title: Doxorubicin-enriched, ALDHbr mouse breast cancer stem cells are sensitive to oncolytic herpes simplex virus type 1

Authors:

Xiufen Zhuang (zhuangxiufen@gmail.com)
Wen Zhang (zhangwen8228@yahoo.cn)
Yatong Chen (chenyatong_2004@163.com)
Xiangping Han (shenqiudetianxie@163.com)
Jie Li (lijiless@yahoo.com)
Yu Zhang (yuzh7324@yahoo.com.cn)
Youhui Zhang (zhyhch@126.com)
Shuren Zhang (biotherapy@caca.sina.net)
Binlei Liu (liubl1@yahoo.com)

Version: 3 Date: 8 June 2012

Author's response to reviews:

Dear Editor:

I would like to submit to BMC cancer this manuscript of original experimental research entitled "Doxorubicin-enriched, ALDHbr mouse breast cancer stem cells are sensitive to oncolytic herpes simplex virus type 1".

Cancer stem cells (CSCs) are responsible for cancer progression, recurrence, metastasis and resistance to conventional therapies. We tested whether oncolytic herpes simplex virus type 1 (HSV1) could eradicate chemoresistant CSCs. Targeting CSCs with oncolytic HSV1 in combination with standard chemotherapy that kills non-CSCs mainly generated a potent anticancer effect in vivo, which may also be applied to the treatment of human breast cancer.

The submitted manuscript has been approved by all authors. The contents of this manuscript are our original work and have not been published, in whole or in part, prior to or simultaneous with our submission of the manuscript. All animal experiments were approved by the Animal Care and Use Committee of the Cancer Institute & Hospital, Chinese Academy of Medical Sciences and complied with the Guide for the Care and Use of Laboratory Animals.

The manuscript has been edited by American Journal Experts (AJE, Certificate Verification Key: B155-6148-612D-501F-7DB6). No potential conflict of interest exits in the submission of this manuscript.

We graciously appreciate your consideration of our manuscript. Please do not hesitate to contact us if any questions should arise regarding this submission or during the review process.
Yours sincerely,
Xiufen Zhuang
Jun. 8, 2012